Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Tahover, Esther ^a   Uziely, Beatrice ^a   Salah, Azzam ^a   Temper, Mark ^a   Peretz, Tamar ^a   Hubert, Ayala ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bevacizumab; Cancer; Colorectal; HTN; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84871126002     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0327-4     Document Type: Article

References (13)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. doi: 10.1056/NEJMoa032691.
2. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-5. doi: 10.1200/JCO.2003.10.066.
3. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44. doi: 10.1200/JCO.2006.09.6305.
4. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade HTN with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23:460-8. doi: 10.1038/ajh.2010.25.
5. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842-7. doi: 10.1093/annonc/mdp233.
6. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862-70. doi: 10.1634/theoncologist.2009-0071.
7. Maitland ML, Moshier K, Imperial J, Kasza E, Karrison T, Elliot W, Undevia SD, Stadler W, Desai AA, Ratain MJ. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. Am Soc Clin Oncol ASCO; Atlanta GA, USA. J Clin Oncol. 2006;24:18S, abstr 2035.
8. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial HTN as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 2011;68:1207-13. doi: 10.1007/s00280-011-1604-1.
9. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F. An observational study of bevacizumab-induced HTN as a clinical biomarker of antitumor activity. Oncologist. 2011;16:1325-32. doi: 10.1634/theoncologist.2010-0002.
10. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P. HTN and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011;104:599-604. doi: 10.1038/bjc.2011.2.
11. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial HTN correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227-30. doi: 10.1093/annonc/mdn637.
12. Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early HTN (HTN) and clinical outcome with bevacizumab (BV). Am Soc Clin Oncol ASCO; Chicago IL, USA. J Clin Oncol. 2010;28:15s, abstr 3039.
13. CTCAE. Common terminology criteria for adverse events (version 4.02). U.S. Department of Health & Human Services, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda MD, USA. Available online: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE-4.02-2009-09-15-QuickReference- 8.5x11.pdf. (2009) Accessed 16 May 2012.